Cancer HealthCast: NCI Program Unlocks Emerging Proteomic Data to Advance Precision Medicine

Proteomics is an emerging field in cancer care and research. The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) aims to get to the heart of cancer by studying its molecular basis across different cancers. The group believes expanding open-source resources and other data can lead to new treatments in cancer and expand precision medicine. Dr. Henry Rodriguez, the founding director of the Office of Cancer Clinical Proteomics Research at NCI, discusses the program and how the related International Cancer Proteogenome Consortium (ICPC) is helping researchers pull together resources necessary to innovate cancer care.